Figure 4
From: Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model
Ponatinib, but not trametinib, blocks CD8+ T cell proliferation and activation in vitro. (A) Experimental scheme for CD8+ T cell proliferation and activation assay. CD8+ T cells isolated from the spleens of C57BL/6J mice were stained with CFSE and cultured in the presence of plate-bound α-CD3 and soluble α-CD28, along with the indicated concentrations of trametinib and ponatinib, for 48 h. Cells were then analyzed using flow cytometry. Statistical differences between multiple groups were determined via one-way ANOVA with Tukey’s post-test analysis. (B) Proliferation Index was calculated for each group via FCS Express v7.08 software. (C–E) Quantification of CD69+ (C), DNAM-1+ (D), and PD-1+ (E) CD8+ T cells. Results are presented as mean + SD. *p < 0.05; **p < 0.01; ***p < 0.001.
